In a patient with type 2 diabetes and eGFR ~28 mL/min/1.73 m² who has stopped metformin, is it appropriate to start glicazide or empagliflozin (Jardiance)?

Start Empagliflozin (Jardiance), Not Gliclazide

With an eGFR of 28 mL/min/1.73 m², you should initiate empagliflozin (Jardiance) 10 mg daily rather than gliclazide, as SGLT2 inhibitors provide critical kidney and cardiovascular protection at this level of renal function, while sulfonylureas offer no such benefits and carry significant hypoglycemia risk. 1, 2

Why Empagliflozin is the Clear Choice

The 2022 KDIGO guidelines explicitly prioritize SGLT2 inhibitors as first-line therapy alongside metformin for patients with type 2 diabetes and CKD 1. When metformin must be stopped (as in your patient with eGFR <30), empagliflozin becomes even more critical because it provides benefits that extend far beyond glucose control:

Empagliflozin at eGFR 28:

• Can be initiated at eGFR ≥20 mL/min/1.73 m² for cardiovascular and kidney protection 2, 3
• Reduces cardiovascular death and heart failure hospitalization 2
• Slows CKD progression through hemodynamic effects (reduces intraglomerular pressure) 4
• The FDA label confirms use down to eGFR 20 for heart failure indication 3
• Once started, can be continued as eGFR declines further, even to dialysis 2

Critical Dosing Detail:

Start with 10 mg daily 2. While glucose-lowering efficacy diminishes at lower eGFR, the kidney and cardiovascular benefits persist 2. The 25 mg dose offers no additional benefit at this eGFR level 3.

Why Gliclazide is Inferior

Sulfonylureas like gliclazide rank low in the treatment hierarchy for patients with CKD 1. The KDIGO algorithm places them below GLP-1 receptor agonists, DPP-4 inhibitors, and even insulin when additional glycemic control is needed 1.

Major Problems with Gliclazide:

• High hypoglycemia risk in CKD, especially as renal function declines 2
• Requires conservative initiation (1 mg daily) and slow titration 2
• Provides zero kidney or cardiovascular protection 1
• When combined with other agents like GLP-1 agonists, increases hypoglycemia risk further 1

The Treatment Algorithm for This Patient

1. Initiate empagliflozin 10 mg daily immediately 2
2. Monitor for volume depletion in first weeks (though risk is low at eGFR 28) 3
3. If additional glycemic control needed after 3 months, add a GLP-1 receptor agonist (dulaglutide, liraglutide, or semaglutide—all safe at this eGFR with no dose adjustment) 1, 2
4. Only consider DPP-4 inhibitors or insulin if GLP-1 agonists are not tolerated 1
5. Reserve sulfonylureas as a last resort only if all other options exhausted 1

Common Pitfalls to Avoid

Don't wait for glycemic control to worsen before starting empagliflozin. The primary indication here is kidney and cardiovascular protection, not glucose lowering 2, 3. Even if HbA1c is at target, this patient needs empagliflozin.

Don't stop empagliflozin if eGFR drops below 20. Once initiated, continue it for ongoing kidney/CV benefits until dialysis 2.

Don't combine empagliflozin with gliclazide initially. If glycemic control is inadequate on empagliflozin alone, GLP-1 agonists are strongly preferred as the next step 1, 2.

Monitor for genital mycotic infections (6% incidence vs 1% placebo), especially in women 2. These are usually easily treated but require patient education.

Evidence Strength

This recommendation is based on Level 1B evidence from KDIGO 2022 1 and the ADA/KDIGO consensus report 2, representing the highest quality guidelines from the most authoritative sources in diabetes and kidney disease management. The EMPA-REG OUTCOME trial demonstrated that empagliflozin slows kidney function decline through sustained hemodynamic effects 4, while no such data exists for sulfonylureas.